Volume 90 Issue 10 | p. 16 | Concentrates
Issue Date: March 5, 2012

GSK And Angiochem In Rare-Diseases Pact

Department: Business
Keywords: lysosomal storage diseases, enzyme replacement therapy, rare diseases

To bolster its rare-diseases program, Glaxo­SmithKline is teaming up with Montreal-based Angiochem to develop treatments for lysosomal storage diseases. Angiochem gets an up-front payment of as much as $31.5 million plus research funding it will use to develop enzyme replacement therapies (ERTs) that can cross the blood-brain barrier. Current ERTs are unable to address the neurological symptoms caused by lysosomal storage diseases. Angiochem’s engineered-peptide technology overcomes those limitations by binding to the LRP1 receptor, which provides a gateway into the brain.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment